Sarepta Stock Drops After Downgrade and FDA Probe. The Crisis Explained.
The outlook for shares is bleak after another batch of worrying headlines.
Sarepta Therapeutics: Beaten Down, But Not Out
SRPT stock now trades at book for the first time ever, despite historically commanding 7x–10x multiples. ELEVIDYS remains FDA-approved for ambulant use and may regain broader access with new protocols underway. Sarepta has $850M in cash, $500M+ in quarterly revenue, and is cutting $400M in costs by 2026.
Opinion | The Sarepta Mugging and Drug Innovation
The Trump FDA tries to kill a therapy that has helped boys with a deadly diagnosis.
US FDA investigates third death after treatment with Sarepta's gene therapy Elevidys
The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received Sarepta Therapeutics' muscular disorder gene therapy Elevidys.
How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals
Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price due to concerns over milestone payments and clinical program continuity. Arrowhead's financial position remains strong, even with a reduced runway caused by the lack of promised milestone payments from Sarepta. In today's article, I discuss a range of potential outcomes for the collaboration between Sarepta Therapeutics and Arrowhead Pharmaceuticals and what Arrowhead can do with its pipeline and financials.
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
Sarepta stock down as it halts U.S. Elevidys shipments after FDA pressure and safety concerns tied to patient deaths due to liver failure.
Sarepta Therapeutics' stock slips further as company bows to FDA pressure to halt shipments
Sarepta Therapeutics shares were lower in premarket trading on Tuesday, as the drugmaker relented to a Food and Drug Administration request to halt shipments of a gene therapy.
Sarepta Stock Falls. Why It's Caving Into the FDA and What Comes Next.
The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.
Sarepta Therapeutics: Why Is SRPT Stock Crashing?
Sarepta Therapeutics has plunged to new lows below $13, down over 35% in recent trading, after rejecting the FDA's request to voluntarily halt all shipments of Elevidys following a third death tied to the gene therapy. Just days after our previous analyses highlighted the company's apparent undervaluation following its restructuring, its defiant stance has now triggered fresh investor concerns, validating the regulatory risks associated with biotech stocks.
Sarepta stock extends decline as company declines FDA call to withdraw drug
Sarepta Therapeutics traded lower on Monday, extending a slide as the company took the unusual step of refusing a Food and Drug Administration request to stop selling a drug tied to three deaths.
Sarepta Therapeutics, Inc. (SRPT) Strategic Restructure and ELEVIDYS Label Update Call Transcript
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Strategic Restructure and ELEVIDYS Label Update Conference Call July 16, 2025 4:30 PM ET Company Participants Douglas S. Ingram - President, CEO & Director Ian Estepan - Corporate Participant Louise Rodino-Klapac - Corporate Participant Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Biren N.
Sarepta shares plunge 30% as future of its gene therapy appears at risk
Shares of Sarepta Therapeutics plunged more than 30% on Friday after Food and Drug Administration Commissioner Marty Makary said the agency is considering whether the company's gene therapy should stay on the market. Sarepta has reported three patient deaths related to its gene therapies.
